StockData
Baxter International Inc logo

Baxter International Inc

BAXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/306% above fair value
$26.16+0.40 (+1.55%)

Close on Nov 18, 2026Market cap $13.53BP/E –Yield 1.99%

Baxter International Target / Actual Patient Enrollment in Started Studies by Year

Baxter International Target / Actual Patient Enrollment in Started Studies: 1,161 in 2025, down 31.2% from a year earlier.

Latest, 2025
1,161
Period ended Dec 31, 2025
Change on a year earlier
-31.2%
1,687 in 2024
History
10 years
Since 2016
Sources
1
ClinicalTrials.gov Registry API v2 (Sponsor: Baxter Healthcare)

Where the 2025 figure comes from

Source: ClinicalTrials.gov Registry API v2 (Sponsor: Baxter Healthcare) ↗

Reported in ClinicalTrials.gov Registry API v2 (Sponsor: Baxter Healthcare).

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Baxter International Target / Actual Patient Enrollment in Started Studies, annual 2016–2025 [Data set]. Compiled from Baxter International SEC filings and investor materials. https://stockdatahq.com/stocks/bax/kpis/ct-enrollment-started

See every metric in the Baxter International KPI table. Data updated Nov 18, 2026.

See a number that looks wrong?